InsiderTrades

Form 4 for AMLX Amylyx Pharmaceuticals, Inc.

Accepted 2023-05-18 00:00:00 ET · period of report 2023-05-16 · accession 0000899243-23-013289 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-05-18 2023-05-16 AMLX FRATES JAMES M CFO M - OptEx $6.88 +32.5K 88.2K +58% +$223.6K
DM 2023-05-18 2023-05-16 AMLX FRATES JAMES M CFO S - Sale+OE $26.94 -32.5K 55.7K -37% -$875.6K
D 2023-05-18 2023-05-16 AMLX FRATES JAMES M CFO M - OptEx $0.00 -32.5K 382.0K -8% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-05-16 M A 32,500 $6.88 88,176 D — —
2 Common Common Stock 2023-05-16 S D 32,000 $26.93 56,176 D — — (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.36 to $27.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
3 Common Common Stock 2023-05-16 S D 500 $27.60 55,676 D — — (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.59 to $27.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
4 Derivative Stock Option (right to buy) 2023-05-16 M D 32,500 $0.00 382,000 D $6.88 · — to 2031-01-25 32,500 Common Stock (F5) 113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter.